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The regulation of platelets by oxidants is critical for vascular health andmay explain thrombotic complications in diseases such as diabetesand dementia, but remains poorly understood. Here, we describe a
novel technique combining electron paramagnetic resonance spectroscopy
and turbidimetry, which has been utilized to monitor simultaneously
platelet activation and oxygen radical generation. This technique has been
used to investigate the redox-dependence of human and mouse platelets.
Using selective peptide inhibitors of NADPH oxidases (NOXs) on human
platelets and genetically modified mouse platelets (NOX1-/- or NOX2-/-), we
discovered that: 1) intracellular but not extracellular superoxide anion gen-
erated by NOX is critical for platelet activation by collagen; 2) superoxide
dismutation to hydrogen peroxide is required for thrombin-dependent acti-
vation; 3) NOX1 is the main source of oxygen radicals in response to colla-
gen, while NOX2 is critical for activation by thrombin; 4) two platelet mod-
ulators, namely oxidized low density lipoproteins (oxLDL) and amyloid
peptide β (Aβ), require activation of both NOX1 and NOX2 to pre-activate
platelets. This study provides new insights into the redox dependence of
platelet activation. It suggests the possibility of selectively inhibiting platelet
agonists by targeting either NOX1 (for collagen) or NOX2 (for thrombin).
Selective inhibition of either NOX1 or NOX2 impairs the potentiatory
effect of tested platelet modulators (oxLDL and Aβ), but does not complete-
ly abolish platelet hemostatic function. This information offers new oppor-
tunities for the development of disease-specific antiplatelet drugs with lim-
ited bleeding side effects by selectively targeting one NOX isoenzyme.  
A novel combinatorial technique for 
simultaneous quantification of oxygen 
radicals and aggregation reveals unexpected
redox patterns in the activation of platelets
by different physiopathological stimuli 
Dina Vara,1 Eugenia Cifuentes-Pagano,2 Patrick J. Pagano2 and Giordano Pula1
1Institute of Biomedical and Clinical Science, University of Exeter Medical School, Exeter,
UK and 2Department of Pharmacology and Chemical Biology and Vascular Medicine
Institute, School of Medicine, University of Pittsburgh, Pittsburgh, PA, USA
ABSTRACT
Introduction
Platelets are anucleated circulating cells responsible for initiating hemostasis via
thrombus formation and blood clotting. The regulation of platelets is of primary
importance for cardiovascular medicine and for the discovery of new drugs to treat
cardiovascular diseases.1 In addition to canonical signaling pathways depending on
protein kinase activity,2 platelets are regulated in a redox-dependent manner. Several
lines of evidence suggest that platelets are modulated by extracellular reactive oxygen
species (ROS)3 and that platelet activation is essentially dependent on the generation
of endogenous ROS.4-6  Therefore, the study of platelet regulation and hemostasis is
shedding light on the interface between ROS biochemistry and cellular physiology.
Superoxide anion (O2•−) from exogenous sources or endogenously produced by
platelets is shown to significantly increase platelet aggregation and thrombus forma-
tion.7 O2•− has a pre-eminent role in biology and pathophysiology, as it serves as a
progenitor for formation of hydrogen peroxide (H2O2), peroxynitrite (ONOO•−) and
hydroxyl radical (HO•), and thereby plays a key role in the post-translational oxida-
tive modification of proteins.8 The work of several research groups has focused on
NADPH oxidases (NOX) as important sources of ROS in
platelets responsible for the regulation of platelet respon-
siveness.9-15 Despite the increased interest in this aspect of
platelet biology and hemostasis regulation, progress within
this field is hampered by the lack of reliable and quantita-
tive techniques for the analysis of platelet oxidative sta-
tus.16,17 This has made it challenging to completely appreci-
ate the importance of endogenous and exogenous oxidants
on the regulation of platelet signaling pathways and on the
balance between hemostasis and thrombosis in health and
disease. Indirectly, this has impeded the development of
pharmacological treatments for thrombotic conditions
based on the control of ROS generation. We addressed this
biomedical need by combining the measurement of platelet
activation (using turbidimetry18) and the simultaneous
measurement of intracellular or extracellular oxygen radi-
cals [using electron paramagnetic resonance (EPR) or EPR
spectroscopy19,20] into one multiplex technique that allows
the accurate study of the oxidative status and function of
human platelets. 
This technique is likely to find application in clinical prac-
tice, where the simultaneous analysis of platelet responsive-
ness and oxidative stress can help develop more advanced
diagnostics for patients at risk of thrombotic diseases. It
could also find application in drug discovery, as NOX mod-
ulation is becoming an important therapeutic strategy in
several diseases.21,22 In the cardiovascular field, in order to
avoid side effects and bleeding complications of antithrom-
botic drugs, modern drug discovery aims to develop target-
ed approaches that interfere with the contribution of
platelets to pathological alterations of the vascular system
while preserving their vascular protective functions.23,24
Within this context, it is imperative to deepen our under-
standing of the regulation of platelets in both health and
disease, as redox-dependent regulation of platelets remains
poorly understood.25 Our novel approach can help to clarify
redox-dependent mechanisms regulating platelets and
hemostasis, validate new drug discovery targets, and iden-
tify novel antiplatelet drug candidates.
In this study, we utilized the EPR/turbidimetry technique
to clarify the dynamics of the generation and activation of
oxygen radicals in human platelets in response to physio-
logical and pathological stimuli. The use of NOX1- and
NOX2-selective peptide inhibitors allowed the identifica-
tion of key differences in the involvement of these two
enzymes in the response to platelet agonists and modula-
tors. The application of this technique will further our
understanding of redox-dependent platelet regulation and
may have important consequences for antiplatelet drug dis-
covery, where the quest for truly pathway-specific
inhibitors targeting pathological platelet activation without
interfering with their physiological hemostatic function
remains an unmet objective. 
Methods
Platelet preparation
Human blood was drawn from healthy volunteers by median
cubital vein venepuncture following Royal Devon and Exeter NHS
Foundation Trust Code of Ethics and Research Conduct and under
National Research Ethics Service South West – Central Bristol
approval (Rec. n. 14/SW/1089). Sodium citrate was used as antico-
agulant (0.5% w/v). Platelet rich plasma (PRP) was separated from
whole blood by centrifugation [250xg, 17 minutes (min)], and
platelets were separated from PRP by a second centrifugation step
(500xg, 10 min), in the presence of prostaglandin E1 (PGE1, 40
ng/mL) and indomethacin (10 μM). For mouse platelets, blood was
taken with intracardiac puncture from 12-week old females under
the Home Office license PPL30/3348 and anticoagulated with
0.5% w/v citrate. PRP was separated from whole blood by cen-
trifugation (160xg, 15 min), and platelets were separated from PRP
by a second centrifugation step (600xg, 10 min), in the presence of
prostaglandin E1 (PGE1, 40 ng/mL) and indomethacin (10 μM). 
Electron paramagnetic resonance/turbidimetry assay
2x108 platelets/mL were prepared as described above. Before
adding stimuli, 200 μM CMH or PPH was added to platelets in the
presence of 25 μM deferroxamine and 5 μM diethyldithiocarba-
mate (DETC). Platelet suspensions were loaded onto a Chronolog
700-2 aggregometer with continuous stirring and the turbidimetry
readings were immediately started. 50 μL of platelet-free super-
natant were transferred into the Hirschmann precision
micropipettes and read using an e-scan (Noxygen, Germany). 
Thrombus formation under physiological flow assay
The Bioflux200 system (Fluxion, South San Francisco,
CA, USA) was used to analyze thrombus formation in
human and mouse whole blood under flow. Heparin-anti-
coagulated whole blood was anticoagulated with 5 μ/mL
heparin plus 40 μM D-Phenylalanyl-prolyl-arginyl
Chloromethyl Ketone or PPACK and incubated with scram-
bled or the NOX inhibitory peptides, NoxA1ds and
Nox2ds-tat before the addition of 1 μM 3,3'-dihexyloxacar-
bocyanine iodide (DiOC6) for 10 min before the blood was
added to the wells. Thrombus formation was visualized by
fluorescence microscopy at a shear rate of 1000 sec−1. 
A more detailed description of the methods used is avail-
able in the Online Supplementary Appendix. 
Results
Superoxide anion-dependence of platelet activation by
collagen but not thrombin
Generation of ROS in a living cell can be examined by
EPR spectroscopy using 1-hydroxy-3-methoxycarbonyl-
2,2,5,5-tetramethylpyrrolidine (CMH), an oxygen radical-
specific spin probe.16 This spin probe crosses the plasma
membrane and directly reacts with intracellular oxygen rad-
icals to generate a nitroxide adduct that can be detected by
EPR spectroscopy (Online Supplementary Figure S1A and B).
We combined classical aggregometry (also known as tur-
bidimetry) with CMH-dependent and EPR spectroscopy by
analyzing CMH oxidation in the platelet supernatant while
the aggregation reaction is taking place (Online
Supplementary Figure S1C). EPR is considered a gold stan-
dard for ROS detection and offers the important advantage
of providing a quantification of the generation rate of oxy-
gen radicals. It is in fact possible to build a calibration curve
using known concentrations of the nitroxide adduct (CM●)
(Online Supplementary Figure S2A and B). Once platelet sus-
pension density and incubation time is known, it is  possi-
ble to interpolate experimental data of resonance intensity
to determine CMH oxidation rates (moles per platelet per
min; see formula in Online Supplementary Figure S2C). This
assay allowed us to correlate platelet aggregation induced
by collagen and thrombin with the rate of oxygen radical
generation (measured as rate of CMH oxidation). Collagen
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was tested at concentrations ranging from 1 to 30 µg/mL
and both aggregation kinetics (Figure 1A) and oxygen radi-
cal generation rates at 10 min from stimulus delivery (Figure
1C) were concentration dependent. Similarly to collagen, a
synthetic collagen-related peptide (CRP) that selectively
engages GPVI receptor (but not other collagen-binding
receptors on platelets), also led to concentration-dependent
O2•− formation that was necessary for platelet aggregation
(Online Supplementary Figure S3). Thrombin also showed
concentration dependence of both EPR  (Figure 1B) and
aggregation (Figure 1D) responses between 0.03 and 1
unit/mL. Online Supplementary Table S1 shows the EC50 val-
ues of these three agonists for EPR detection of superoxide
anion generation and aggregation response. 
In order to confirm the chemical nature of the oxygen
radicals generated by platelets upon activation and detected
Redox-dependent regulation of platelets 
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Figure 1. Oxygen radical generation by
platelets activated by physiological stimuli col-
lagen and thrombin. Washed human platelets
were prepared as described. Collagen was test-
ed at concentrations ranging from 1 to 30
μg/mL  (A and C), while thrombin was tested
from 0.03 to 1 unit/mL  (B and D). Electron
paramagnetic resonance (EPR) was used to
measure oxygen radicals formation as 1-
hydroxy-3-methoxycarbonyl-2,2,5,5-tetram-
ethylpyrrolidine (CMH) oxidation rates [32.7
and 37.3 attomoles per platelet per minute
(min), respectively] (A and C) and aggregation
was simultaneously assessed by turbidimetry
(B and D). For either technique, representative
examples are shown in top panels, while quan-
tification is shown in the bottom panels.
Aggregation curves up to 5 min are shown,
while EPR resonance readings were taken after
10 min of stimulation. Examples of EPR traces
and aggregation curves are representative of 4
independent experiments. Statistical analysis
was performed by one-way ANOVA with
Bonferroni post-hoc test. *P<0.05 compared to
resting platelets. N=4 for (A-D).
A
C
B
D
by EPR, we utilized cell-permeant pegylated superoxide
dismutase (PEG-SOD), which scavenges O2•− by dismuting
it into H202. The EPR signal detected in human platelets
stimulated by collagen and thrombin was abolished by
PEG-SOD, suggesting that O2•− is the oxygen radical
species generated under these conditions (Online
Supplementary Figure S4A and C,  respectively). The genera-
tion of O2•− radicals appeared necessary for platelet activa-
tion by collagen, as the scavenging of this oxygen radical
by PEG-SOD significantly inhibited aggregation in
response to this agonist (Online Supplementary Figure S4B).
On the other hand, thrombin-dependent aggregation was
not affected by PEG-SOD, suggesting that O2•− is not an
essential component of the signaling cascades induced by
this agonist. Similarly to collagen, both EPR and aggrega-
tion signals in response to CRP were abolished by PEG-
SOD (Online Supplementary Figure S3C and D). The data
obtained with PEG-SOD were confirmed using another
O2•− scavenger, 4-hydroxy-2,2,6,6-tetramethylpiperidin-1-
oxyl (or TEMPOL). TEMPOL abolishes the EPR signal in
response to either collagen or thrombin (Online
Supplementary Figure S5A and C,  respectively), while only
the aggregation response to collagen but not thrombin
(Online Supplementary Figure S5C and D, respectively) is
inhibited. Interestingly, the non-selective antioxidant and
cell permeable amino acid N-acetyl cysteine (NAC) inhibits
aggregation induced by both collagen and  thrombin, sug-
gesting that the thrombin responses depend on oxidative
reactions, but that O2•−, per se, is not the oxidant species
involved in this response (Online Supplementary Figure S5C
and D). In order to confirm that the CMH-based EPR did
not detect H202 (another major ROS) in our hands, we per-
formed experiments in the presence of catalase (CAT, non-
cell permeable) and pegylated catalase (PEG-CAT, cell per-
meable), which convert H202 to water (Online
Supplementary Figure S6). No effect of either enzymes on
the collagen- or thrombin-induced EPR signal was
observed, proving the specificity of the CMH-based EPR
measurements for oxygen radicals and O2•− in particular. 
Low levels of superoxide anion are released by platelets
although they are not required for platelet activation
We demonstrated that the CMH-based EPR spectroscopy
predominantly measures intracellular but not extracellular
platelet O2•− in response to either collagen or thrombin
(Online Supplementary Figure S7), as the non-pegylated and
thus non-cell permeable version of the enzyme superoxide
dismutase (SOD) did not affect the responses. Interestingly,
we also utilized a non-cell permeable EPR probe called 1-
Hydroxy-4-phosphono-oxy-2,2,6,6-tetramethylpiperidine
(or PPH) to detect extracellular O2•− released by platelets
(Online Supplementary Figure S8A-D). Noticeably, the scav-
enging of extracellular O2•− with SOD was effective in abol-
ishing the PPH-based signal (Online Supplementary Figure
S8E and F), but did not affect collagen- or thrombin-induced
aggregation (Online Supplementary Figure S8G and H), sug-
gesting that extracellular O2- does not participate in the
process of platelet activation. In addition, we confirmed the
formation of H202 in response to collagen or thrombin using
the H2O2-specific probe Amplex Red (Online Supplementary
Figure S9A and B) and that catalase effectively quenched the
signal. More importantly, the degradation of H202 by cata-
lase or pegylated catalase inhibited platelet aggregation
stimulated by thrombin, but not collagen (Online
Supplementary Figure S9C-F). This suggests that H202 is a crit-
ical component of the signaling triggered by thrombin but
not collagen.  
Differential role of NADPH oxidases 1 and 2 in 
collagen- and thrombin-dependent activation of human
platelets
We utilized the combinatorial EPR/aggregometry that
we developed to assess the role of NOX1 and NOX2 in
platelet activation by collagen and thrombin. In experi-
ments illustrated in Figure 2, we used the NOX1-specific
inhibitory peptide NoxA1ds to assess the role of this
enzyme in platelet activation.26 NOX1 inhibition almost
completely inhibited oxygen radical formation in response
to collagen (Figure 2A), but not thrombin (Figure 2B). In
parallel, collagen- (Figure 2C) but not thrombin-dependent
(Figure 2D) aggregation was inhibited by NoxA1ds.
Importantly a scrambled version of the peptide was used
as control. Taken together, these data suggest that NOX1
is activated and participates in the signaling of platelet
activation in response to collagen but not thrombin. We
also tested the role of NOX2 using the specific inhibitory
peptide Nox2ds-tat.27,28 Both collagen- and thrombin-
dependent oxygen radical formation are significantly
impaired by NOX2 inhibition (Figure 3A and B, respec-
tively). Interestingly, although the inhibition of the throm-
bin response by Nox2ds-tat reduces oxygen radical forma-
tion to basal levels, the inhibition of collagen-induced oxy-
gen radical levels is only partial (i.e. in the presence of
Nox2ds-tat the oxygen radical levels induced by collagen
are significantly higher than resting controls). This is
reflected in the aggregation data, which show complete
inhibition by Nox2ds-tat of the aggregation induced by
thrombin but only marginal inhibition of the response to
collagen (Figure 3D and C, respectively). This is consistent
with NOX1 playing a larger role than NOX2 in collagen-
induced platelet aggregation. The data obtained with col-
lagen were essentially confirmed using the synthetic lig-
and for GPVI CRP (Online Supplementary Figure S10),
which suggests that GPVI is the key receptor linking col-
lagen-dependent platelet activation to oxygen radical gen-
eration and determines the redox patterns triggered by
collagen in platelets. The active engagement of NOX1 and
NOX2 in collagen and thrombin signaling was confirmed
by co-immunoprecipitation of these two core subunits
with respective essential cytosolic components of each
complex. NOX1 is co-immunoprecipitated with its canon-
ical activating subunit NOXA129 in the presence of colla-
gen, which is consistent with NOX1 being post-transla-
tionally activated in response to collagen (Figure 4A).
NOX2 appears to be co-immunoprecipitated with its
canonical organizing subunit p47phox in the presence of
thrombin and weakly in the presence of collagen (Figure
4B). This aligns with the conclusions reached using our
EPR and aggregation experiments, i.e. that collagen acti-
vates a primarily NOX1-dependent response, while
thrombin activates primarily NOX2. Accordingly, whole
blood thrombus formation experiments on collagen
showed that NOX1 inhibition with NoxA1ds abolishes
thrombus formation (Figure 4C), while NOX2 inhibition
by Nox2ds-tat induces only a marginal inhibition (Figure
4D). Experiments in platelets from wild-type, NOX1-/- or
NOX2-/- mice confirmed the centrality of NOX1 for colla-
gen signaling with marginal involvement of NOX2 in the
aggregation response (Figure 5A and B), while NOX2 is
critical for thrombin signaling (Figure 5C).    
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Role of NOX1 and NOX2 in mediating the effect on
platelets of weak agonists/positive modulators 
oxidized LDL (oxLDL) and amyloid beta (Aβ1-42)
Using these tools (NoxA1ds26 and Nox2ds-tat27,28), we
determined that NOX1 or NOX2 play an equivalent role in
the generation of superoxide anion in response to oxLDL
(Figure 6A) and that both enzymes are required for the
stimulation of the modest aggregation induced by this
modulator (Figure 6B). As suggested by the inhibition of
aggregation by PEG-SOD, O2•− is the oxidant molecule
required for the activation of platelets by oxLDL. It is
important to note how oxLDL elicits a very modest aggre-
gation (both as size and kinetic of the response), which con-
forms to the designation of oxLDL as a modulator rather
than agonist (i.e. exerting its effect by enhancing the
responsiveness of platelets to low agonist levels). In fact,
low concentrations of collagen (Figure 6C) or thrombin
(Figure 6D) characterized by the ability to induce no/low
aggregation, resulted able to induce a robust platelet aggre-
gation in the presence of ox-LDL. The synergistic effect of
oxLDL in combination with thrombin or collagen was
inhibited by NoxA1ds (Figure 6C) or Nox2ds-tat (Figure
6D), respectively. We could not test NoxA1ds on ox-LDL +
collagen or Nox2ds-tat on oxLDL + thrombin, because, as
shown above, NoxA1ds inhibits collagen directly and
Nox2ds-tat inhibits thrombin directly.  Similarly, Aβ1-42
induces O2•− formation via activation of NOX1 and NOX2
(Figure 7A), which leads to a modest platelet aggregation
Redox-dependent regulation of platelets 
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Figure 2. NOX1 is specifically involved in
platelet activation by collagen but not
thrombin. 1-hydroxy-3-methoxycarbonyl-
2,2,5,5-tetramethylpyrrolidine (CMH) was
utilized for the detection of oxygen radi-
cals generated by platelets. 10 μg/mL col-
lagen (A) or 0.1 unit/mL thrombin (B)
were tested. 10 μM of NoxA1ds abolished
the electron paramagnetic resonance
(EPR) response measured in the pres-
ence of collagen. The scrambled peptide
at the same concentration (scNoxA1ds)
was used as a negative control.
Interestingly, the inhibition of NOX1 by
NoxA1ds also inhibited collagen-depen-
dent (C), but not thrombin-dependent (D)
platelet aggregation. Aggregation curves
for up to 5 minutes (min)  are shown,
while  EPR  resonance readings were
taken after 10 min of stimulation.
Examples of EPR traces and aggregation
curves are representative of 3 or more
independent experiments. Statistical
analysis was performed by one-way
ANOVA with Bonferroni post-hoc test for
EPR. *P<0.05 compared to resting
platelets or t-test for aggregation.
*P<0.05 compared to scrambled control.
N=3 for (A-D).
A
C
B
D
(Figure 7B). On the other hand, similarly to oxLDL, Aβ1-42
displays the ability to synergistically increase the aggrega-
tion response to low concentrations of collagen (Figure 7C)
or thrombin (Figure 7D). As proved with inhibitory pep-
tides NoxA1ds26  and Nox2ds-tat,27,28  the synergistic effect
on collagen- or thrombin-induced aggregation is NOX1- or
NOX2-dependent, respectively. We could not test NoxA1ds
on Aβ1-42 + collagen or Nox2ds-tat on Aβ1-42 + thrombin,
because, as shown above, NoxA1ds inhibits collagen direct-
ly and Nox2ds-tat inhibits thrombin directly. Transgenic
mice NOX1-/- and NOX2-/- were utilized to assess the NOX-
dependence of the responses to oxLDL and Aβ1-42. As ox-
LDL coating of surfaces is not commonly used and there is
no accepted protocol for this procedure, we tested the
effect of oxLDL added to mouse blood on thrombus forma-
tion on low levels (i.e. 0.05 mg/mL) of collagen coating
(Figure 8A). These data showed that oxLDL potentiates the
thrombus formation on collagen in a NOX2-dependent
manner (as it was not evident in NOX2-/- blood). NOX1
ablation inhibits collagen responses directly, therefore we
could not investigate the role of NOX1 in the potentiation
of responses to this agonist by oxLDL. The ablation of
either NOX1 or NOX2 silencing significantly also impairs
thrombus formation at physiological arterial shear on
absorbed Aβ1-42 (1,000 sec-1) (Figure 8C). At low shear
(200 sec-1), mouse platelets display low levels of adhesion
to absorbed Aβ1-42 without formation of thrombi, which
was inhibited by NOX1 genetic silencing but unaffected by
D. Vara et al.
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Figure 3. NOX2 is activated by
both collagen and thrombin, but
essential only for platelet aggre-
gation induced by thrombin. 1-
hydroxy -3-methoxycarbonyl -
2,2,5,5-tetramethylpyrrolidine
(CMH) was utilized for the detec-
tion of oxygen radicals generated
by platelets. 10 μg/mL collagen
(A) or 0.1 unit/mL thrombin (B)
were tested. 10 μM of Nox2ds-tat
inhibited the electron paramag-
netic resonance (EPR)  response
measured in the presence of
either collagen or thrombin,
although the collagen-dependent
response remained significantly
higher than resting levels of oxy-
gen radical formation. The scram-
bled peptide at the same concen-
tration (scNox2ds-tat) was used
as a negative control.
Interestingly, the inhibition of
NOX2 by Nox2ds-tat also inhibit-
ed thrombin-dependent  (D), but
not collagen-dependent (C)
platelet aggregation. Examples of
EPR traces and aggregation
curves are representative of 3 or
more independent experiments.
Statistical analysis was per-
formed by one-way ANOVA with
Bonferroni post-hoc test for EPR.
*P<0.05 compared to resting
platelets or t-test for aggregation.
*P<0.05 compared to scrambled
control. N=4 for (B and D), n=5
for (A), and n=7 for (C).
A
C
B
D
NOX2 ablation (Online Supplementary Figure S11). As these
modulators induce little or no aggregation on their own, we
analyzed the modulatory effect of oxLDL and Aβ1-42 in
aggregation experiments using NOX1-/- and NOX2-/- mouse
platelets. We showed that oxLDL (Figure 8B) and Aβ1-42
(Figure 8D) potentiate the aggregation induced by collagen
in wild-type mice but not in NOX2-/- mice, and the aggrega-
tion stimulated by thrombin in wild-type mice but not in
NOX1-/- mice. The potentiation of collagen response could
not be tested in NOX1-/- mice, which do not respond to this
Redox-dependent regulation of platelets 
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Figure 4. NOX1 is the main source of superoxide anions in human platelet response to collagen, while NOX2 is the main source of thrombin-dependent reactive
oxygen species (ROS). The activation of NOX1 (A) and NOX2 (B) was assessed by co-immunoprecipitation with their canonical activating and organizing subunits
NOXA1 and p47phox, respectively. 400 μL of platelet suspension (4x108 platelets/mL) were stimulated with 10 μg/mL collagen or 0.1 unit/mL thrombin or vehicle solu-
tion (Tyrode’s buffer) for 10 minutes (min) before gentle cell lysis (NP40 buffer). Specific NOX1 or NOX2 antibodies and Protein A/G were used to immunoprecipitate
the NOX complexes (which by extension should include their regulatory subunits after activation). The immunoprecipitates were tested by immunoblotting using
NOX1, NOXA1, NOX2 or p47phox antibodies (as indicated). The data are representative of 4 independent experiments. The functional role of NOX1 and NOX2 in col-
lagen-dependent platelet activation was assessed in a whole blood flow assay (C and D). Platelets were stained with DiOC6 as described and the Bioflux platform
(Fluxion, San Francisco, CA, USA) was utilized to assess the thrombus formation induced by collagen under physiological flow (1000 sec-1). The experiments were
performed in the presence of NoxA1ds or its negative scrambled control (C) or Nox2ds-tat or its negative scrambled control (D). Images were taken at 10 min of flow
and are representative of 4 independent experiments. They were quantified by assessing the surface area coverage by platelets (C and D, bottom). Statistical signif-
icance was tested by t-test. *P<0.05 compared to scrambled control. N=4 for (C and D).    
A
C
B
D
stimulus, while the potentiation of thrombin responses
could not be tested in NOX2-/-, for the same reason. 
Discussion
The study of platelet function is critical to understanding
vascular homeostasis and disease. A thorough understand-
ing of the redox-dependent regulation of platelet function
has been hampered by the lack of a reliable technique to
measure intracellular ROS.16,17 We have resolved this prob-
lem by optimizing an EPR-based technique for the detec-
tion of oxygen radicals and combining it with a classical tur-
bidimetric assay for the simultaneous measurement of
platelet aggregation. Although EPR has previously been
used for the analysis of ROS formation in live cells;16,17 this
technique has never been applied to the study of platelet
redox signaling. We utilized the assay developed here to
clarify several unknown aspects of the regulation of platelet
activity by endogenous oxidants. 
The molecular mechanisms underlying the redox
dependence of platelet activation in response to collagen,
thrombin, and oxidized LDL are summarized in Online
Supplementary Figure S12. Although, the dependence of
platelet activation on the generation of endogenous ROS
has been described,1-6 here for the first time we elucidated
the chemical nature of the ROS involved in the signaling of
different platelet agonists and modulators. O2•− are generat-
ed in response to all tested agonists and modulators, but
although these ROS are directly involved in the signaling of
collagen, oxLDL and Aβ1-42, their dismutation to hydrogen
peroxide is necessary for the signaling of thrombin. The lit-
erature on this aspect of platelet biology is quite inconclu-
sive because of the use of different techniques and condi-
tions. Although previous studies reported the generation of
hydrogen peroxide in response to thrombin (and leading to
D. Vara et al.
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Figure 5. NOX1- and NOX2-dependence
of collagen and thrombin aggregation
and superoxide generation tested in
transgenic mice. Platelets were isolated
for wild-type (C57BL6/J), NOX1-/- or
NOX2-/- mice exsanguinated via intracar-
diac puncture and resuspended at
2x108 platelets/mL density. Platelets
were stimulated with 3 μg/mL collagen
(A) or 0.1 unit/mL thrombin (C).
Aggregation (left) and superoxide anion
formation (right) were measured as
described for 5 and 10 minutes (min),
respectively. (B) The functional role of
NOX1 and NOX2 in collagen-dependent
platelet activation was also assessed in
a whole blood flow assay. Platelets were
stained with DiOC6 and the Bioflux plat-
form (Fluxion, San Francisco, CA, USA)
was utilized to assess the thrombus for-
mation induced by collagen under phys-
iological flow (1,000 sec-1). Images
were taken at 10 min of flow and are
representative of 4 independent experi-
ments. They were quantified by assess-
ing the surface area coverage by
platelets with Image J. Data are repre-
sentative of 4 independent experi-
ments. Statistical analysis was per-
formed by one-way ANOVA with
Bonferroni post-hoc test. *P<0.05. N=4
for (A-C).
A
B
C
apoptosis),30 this study for the first time highlights a signifi-
cant difference in the role of hydrogen peroxide in the
responses to collagen and thrombin. Our observations on
the link between thrombin-dependent activation and
hydrogen peroxide contradict previous reports pointing to a
role for hydrogen peroxide in collagen but not thrombin
signaling.31 The experimental differences in our and previ-
ous studies are extensive and the poor specificity of the
tools used for older studies (e.g. 2',7'–dichlorofluorescein
diacetate or DCFDA) are potentially responsible for these
discrepancies. 
Another important addition to our understanding of
redox regulation of platelets is the clarification of whether
oxidants act intracellularly or extracellularly. Our data clear-
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Figure 6. NOX1 and NOX2 are required for the induction of superoxide anion formation and platelets activation by oxidized low density lipoprotein (oxLDL). Oxygen
radical generation (A) and platelet aggregation (B) in response to oxLDL were measured as described. 10 μM of scrambled NoxA1ds (scNoxA1ds), NoxA1ds, scram-
bled Nox2ds-tat (scNox2ds-tat), Nox2ds-tat or 100 unit/mL of PEG-SOD were pre-incubated 10 minutes (min) before platelet stimulation with  50 ng/mL oxLDL.
Examples of electron paramagnetic resonance (EPR) traces and aggregation curves are representative of 4 independent experiments. Statistical analysis was per-
formed by one-way ANOVA with Bonferroni post-hoc test. *P<0.05. N=3 for (B) and n=4 for (A). The effect of oxLDL as platelet modulator was investigated by tradi-
tional aggregometry (C and D). Pre-incubation with 50 ng/mL oxLDL for 10 min was followed by stimulation with 3 μg/mL collagen (C) or 0.03 unit/mL thrombin (D).
In order to test the dependence of the modulatory effect of oxLDL on NOX1 and NOX2, 10 μM scrambled NoxA1ds (scNoxA1ds), NoxA1ds, scrambled Nox2ds-tat
(scNox2ds-tat), Nox2ds-tat were pre-incubated (10 min before addition of oxLDL). Aggregation curves are representative of 4 independent experiments.  
A B
C D
ly suggest that platelet O2•− acts intracellularly in these
responses, as only cell permeable scavenger can affect their
activity (i.e. PEG-SOD), while hydrogen peroxide is likely
to be formed by dismutation of intracellular O2•− and
released extracellularly, where it potentiates platelet
responses induced by thrombin (as proved by the effect of
non-cell permeable catalase shown in Online Supplementary
Figure S6).  These findings add significantly to our under-
standing of platelet redox regulation and are in agreement
with previous suggestions of an intracellular function for
O2•− .32,33 It is also in agreement with the observation of a
positive regulatory role for extracellular hydrogen peroxide
in thrombin-induced responses34 and a role for extracellular
oxidants in the regulation of platelet surface receptor func-
D. Vara et al.
1888 haematologica | 2019; 104(9)
Figure 7. NOX1 and NOX2 are required for the induction of superoxide anion formation and platelet activation by amyloid peptide β 1-42. Oxygen radical generation
(A) and platelet aggregation (B) in response to amyloid peptide β 1-42 (Aβ1-42) were measured as described. 10 μM of scrambled NoxA1ds (scNoxA1ds), NoxA1ds,
scrambled Nox2ds-tat (scNox2ds-tat), Nox2ds-tat or 100 unit/mL of PEG-SOD were pre-incubated 10 minutes (min) before platelet stimulation with  20 μM Aβ1-42.
Examples of electron paramagnetic resonance (EPR) traces and aggregation curves are representative of 4 independent experiments. Statistical analysis was per-
formed by one-way ANOVA with Bonferroni post-hoc test. *P<0.05. N=3 for (A and B). The effect of Aβ1-42 as platelet modulator was investigated by traditional aggre-
gometry (C and D). Pre-incubation with 20 μM Aβ1-42 for 10 min was followed by stimulation with 3 μg/mL collagen (C) or 0.03 unit/mL thrombin (D). In order to
test the dependence of the modulatory effect of Aβ1-42 on NOX1 and NOX2, 10 μM scrambled NoxA1ds (scNoxA1ds), NoxA1ds, scrambled Nox2ds-tat (scNox2ds-
tat), Nox2ds-tat were pre-incubated (10 min before addition of Aβ1-42). Aggregation curves are representative of 4 independent experiments. 
A B
C D
tion by protein disulphide isomerases (PDI).35 Regarding
the redox-dependence of the collagen signaling in platelets,
although further studies are required, protein tyrosine phos-
phatases (PTP) are the most likely link between redox and
conventional signaling in platelets.36 The oxidative inactiva-
tion of protein phosphatases has in fact been suggested to
play a key role in the activation and regulation of the patho-
physiological roles of platelets.37 The Src Homology
Phosphatase 2 (SHP2) has been shown to play an important
role as a negative regulator of platelet activation,38  and
recent studies demonstrated that ROS generated during
platelet activation oxidize and inhibit SHP2. This, in turns,
facilitates the activation of protein kinase-mediated signal-
ing pathways and drives the processes associated with cell
activation (e.g. adhesion receptor activation, shape change,
etc.).37,39 
In this study, we also highlight the differential involve-
ment of NOX1 and NOX2 in physiological agonist signal-
ing (i.e. collagen and thrombin). NOX1 is essential for the
signaling of collagen with NOX2 inhibition only partially
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Figure 8. Experiments on trans-
genic mice suggest that NOX1
and NOX2 are required for the
effect of amyloid peptide β 1-
42 and oxidized low density
lipoprotein (oxLDL). Platelets
from wild-type, NOX1-/- or NOX2-/-
mice were stained with DiOC6
and the Bioflux platform
(Fluxion, San Francisco, CA,
USA) was utilized to assess the
thrombus formation induced by
collagen under physiological
flow. (A) Ibidi Vena8+ flow cham-
bers were coated with 0.05
mg/mL collagen and whole
blood was treated with 50
ng/mL native LDL (nLDL) or
oxLDL. (C) Ibidi Vena8+ flow
chambers were coated with 20
μM Aβ1-42 or scrambled con-
trol peptide (ScAβ1-42). The
shear rate utilized was 1,000
sec-1, which leads to thrombus
formation. Images were taken
at 10 minutes (min) of flow and
are representative of 4 inde-
pendent experiments. Images
were quantified by assessing
the surface area coverage by
platelets with Image J. Data are
representative of 4 independ-
ent experiments. Statistical
analysis was performed by one-
way ANOVA with Bonferroni
post-hoc test. *P<0.05. N=4 for
(A and C). Aggregation experi-
ments were performed by pre-
treating platelets with 50
ng/mL native LDL (nLDL) or
oxLDL (B) or 20 μM Aβ1-42 or
scrambled control peptide
(ScAβ1-42) (D) for 10 min. Low
level aggregation was then stim-
ulated with either 10 μg/mL col-
lagen or 0.03 unit/mL throm-
bin, as indicated. Aggregation
data are representative of 3
independent experiments.
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reducing collagen-dependent aggregation and O2•− forma-
tion, in both human (Figure 3A and B) and mouse (Figure
5A) platelets. The secondary role of NOX2 in collagen
responses is further demonstrated by thrombus formation
experiments under physiological flow, which is marginally
but significantly reduced by NOX2 inhibition/silencing in
human but not mouse blood (compare Figure 4D and Figure
5B). This discrepancy between thrombus formation in
human and mouse blood could be suggestive of a higher
involvement of NOX2 in collagen responses of human
platelets. In any case, the dominant role of NOX1 in colla-
gen response is clear in our experiments both in human and
mouse platelets. Similarly, NOX2 is essential for the signal-
ing of thrombin without NOX1 involvement in human
platelets (Figure 2C and D) and limited yet significant
involvement in mouse platelets (Figure 5C). This is in agree-
ment with previous indications from our and other
groups,14,40 but in essential disagreement with a recent study
by Delaney et al. in mouse platelets reaching opposite con-
clusions (i.e. NOX1 involvement in thrombin signaling and
NOX2 involvement in collagen signaling).13 Some differ-
ences can be expected between signaling pathways and
redox dependence of human and mouse platelets, which
may explain this discrepancy. Overall, combining human
and mouse platelet data, it is safe to state that thrombin-
dependent aggregation depends very heavily on NOX2
activity (although a role of NOX1 in thrombin was detected
in mouse platelets, which we did not observe in human
platelets), while collagen-induced aggregation was predom-
inantly NOX1-dependent with marginal involvement of
NOX2 (as shown in our human platelet data). So, although
mouse platelets display some engagement of NOX1 in
thrombin responses, species-specific differences cannot
fully explain the discrepancy between our report and
Delaney et al.’s work. The fact that Delaney et al. used male
animals for NOX1 studies and females for NOX2 studies
may explain some of the differences with our study (per-
formed entirely on female animals). Other potentially
important differences are in the platelet isolation procedure,
the concentration of agonists (very low concentration of
thrombin used), and the use of collagen-related peptide
instead of collagen.   
In addition to physiological stimuli, in this study we ana-
lyzed the effect of oxLDL and Aβ1-42, platelet modulators
associated with the thrombotic complications of athero-
sclerosis41 and cerebrovascular amyloid angiopathy
(CAA),42 respectively. Both oxLDL and Aβ1-42 have been
shown to activate platelets and act as positive modula-
tors.15,43 We confirmed the ability of these molecules to
induce partial platelet aggregation. On the other hand, they
were able to significantly increase the responses to low lev-
els of physiological agonists. This mode of action is consis-
tent with the definition of positive modulators or primers,44
which are characterized by the ability to trigger an unwant-
ed hemostatic response and clot formation leading to
thrombosis. The involvement of platelet positive modula-
tors in thrombotic complications associated with diseases is
particularly important for vascular health and relative phar-
macotherapy.45 Interestingly, the aggregation induced by
these primers was also redox-dependent and inhibited by
the O2•− scavenger PEG-SOD. This is in agreement with
previous literature on oxLDL15,46 and Aβ1-42,47 and sup-
ports the hypothesis that platelet primers may act in a
redox-dependent manner.48 
Also intriguing were our conclusions regarding the
involvement of NOX1 and NOX2 in the signaling of
oxLDL and Aβ1-42. We provide compelling evidence in
human platelets with NOX-selective inhibitors Nox2ds-
tat and NoxA1ds or in genetically modified mouse
platelets (NOX1-/- or NOX2-/-) that both NOX1 and NOX2
are activated by oxLDL and Aβ1-42 and that they are both
required for the functional effects of these pathology-asso-
ciated modulators on platelets. These conclusions were
confirmed by experiments with transgenic mouse
platelets, both in thrombus adhesion and aggregation
experiments. Only adhesion to Aβ1-42 under low shear
seemed exclusively NOX1-dependent. This is a low level
adhesion response incapable of properly triggering throm-
bus formation (Online Supplementary Figure S11). These
data may, therefore, suggest a differential involvement of
NOX1 and NOX2 in different molecular events triggered
by Aβ1-42. This hypothesis merits further study for satis-
factory elucidation. The involvement of NOX2 in the sig-
naling of oxLDL has been suggested previously,15,46 while
the involvement of NOX1 is novel. The possibility of
abolishing the effect of oxLDL and Aβ1-42 on platelets by
inhibiting only one of the two NOX may suggest that
both enzymes are required for reaching a threshold in the
superoxide anion levels leading to platelet stimulation.
The similarities between the activity and redox-depen-
dence of oxLDL and Aβ1-42 may suggest that they act on
similar receptors. As suggested by literature for both mol-
ecules, the receptors for these platelet modulators are like-
ly to be CD36.15,49 Importantly, the fact that both platelet
NOX are required for the modulatory activity of oxLDL or
Aβ1-42 offers the opportunity of targeted intervention
without the complete inhibition of the response to physi-
ological agonists. In other words, the inhibition of only
one NOX isozyme could reduce the pro-thrombotic ten-
dencies associated with vascular inflammation without
completely impairing the hemostatic response (i.e. NOX1
inhibition will not impair thrombin response, while
NOX2 inhibition will not impair collagen responses). This
is the ultimate goal of modern antiplatelet drug develop-
ment and may help to resolve the persisting problem of
bleeding risks associated with all existing antiplatelet
treatment.50 
In summary, herein we describe the development and
application of a novel approach to simultaneously monitor
the generation of oxygen radicals and platelet aggregation.
This technique has the potential to become a standard tech-
nique to assess platelet responsiveness and thrombotic risks
associated to vascular conditions in a clinical setting. In
addition, this study allowed the identification of patterns of
platelet regulation and the clarification of the mode of
action of physiological agonists and pathological modula-
tors of platelets. The results of this study also highlight the
potential of NADPH oxidase targeting for the development
of novel antiplatelet drugs with better pharmacodynamic
profiles (i.e. limited bleeding side effects).
Acknowledgments
The authors would like to thank the British Heart Foundation for
sponsoring this research (PG/15/40/31522), the Clinical Research
Facility (CRF) of the University of Exeter and in particular Dr
Bridget Knight for blood collections and Dr Bruno Fink from
Noxygen Science Transfer & Diagnostics GmbH for the technical
support. 
D. Vara et al.
1890 haematologica | 2019; 104(9)
Redox-dependent regulation of platelets 
haematologica | 2019; 104(9) 1891
References
1. Chaudhari K, Hamad B, Syed BA.
Antithrombotic drugs market. Nat Rev
Drug Discov. 2014;13(8):571-572.
2. Stegner D, Nieswandt B. Platelet receptor
signaling in thrombus formation. J Mol
Med (Berl). 2011;89(2):109-121.
3. Iuliano L, Colavita AR, Leo R, Pratico D,
Violi F. Oxygen free radicals and platelet
activation. Free Radic Biol Med.
1997;22(6):999-1006.
4. Watt J, Ewart M-A, Greig FH, Oldroyd KG,
Wadsworth RM, Kennedy S. The effect of
reactive oxygen species on whole blood
aggregation and the endothelial cell-
platelet interaction in patients with coro-
nary heart disease. Thromb Res.
2012;130(2):210-215.
5. Freedman JE. Oxidative stress and platelets.
Arterioscler Thromb Vasc Biol.
2008;28(3):s11-16.
6. Ferroni P, Vazzana N, Riondino S,
Cuccurullo C, Guadagni F, Davi G. Platelet
function in health and disease: from molec-
ular mechanisms, redox considerations to
novel therapeutic opportunities. Antioxid
Redox Signal. 2012;17(10):1447-1485.
7. Krotz F, Sohn HY, Pohl U. Reactive oxygen
species: players in the platelet game.
Arterioscler Thromb Vasc Biol.
2004;24(11):1988-1996.
8. Chondrogianni N, Petropoulos I, Grimm S,
et al. Protein damage, repair and proteoly-
sis. Mol Aspects Med. 2014;35:1-71.
9. Violi F, Pignatelli P. Platelet NOX, a novel
target for anti-thrombotic treatment.
Thromb Haemost. 2014;111(5):817-823.
10. Bartimoccia S, Carnevale R, Sanguigni V, et
al. NOX 5 is expressed in platelets from
patients with chronic granulomatous dis-
ease. Thromb Haemost. 2016;116(1):198-
200.
11. Krotz F, Sohn HY, Gloe T, et al. NAD(P)H
oxidase-dependent platelet superoxide
anion release increases platelet recruit-
ment. Blood. 2002;100(3):917-924.
12. Begonja AJ, Gambaryan S, Geiger J, et al.
Platelet NAD(P)H-oxidase-generated ROS
production regulates alphaIIbbeta3-inte-
grin activation independent of the
NO/cGMP pathway. Blood. 2005;
106(8):2757-2760.
13. Delaney MK, Kim K, Estevez B, et al.
Differential Roles of the NADPH-Oxidase
1 and 2 in Platelet Activation and
Thrombosis. Arterioscler Thromb Vasc
Biol. 2016;36(5):846-854.
14. Vara D, Campanella M, Pula G. The novel
NOX inhibitor 2-acetylphenothiazine
impairs collagen-dependent thrombus for-
mation in a GPVI-dependent manner. Br J
Pharmacol. 2013;168(1):212-224.
15. Magwenzi S, Woodward C, Wraith KS, et
al. Oxidized LDL activates blood platelets
through CD36/NOX2-mediated inhibition
of the cGMP/protein kinase G signaling
cascade. Blood. 2015;125(17):2693-2703.
16. Dikalov SI, Harrison DG. Methods for
detection of mitochondrial and cellular
reactive oxygen species. Antioxid Redox
Signal. 2014;20(2):372-382.
17. Griendling KK, Touyz RM, Zweier JL, et al.
Measurement of Reactive Oxygen Species,
Reactive Nitrogen Species, and Redox-
Dependent Signaling in the Cardiovascular
System: A Scientific Statement From the
American Heart Association. Circ Res.
2016;119(5):e39-75.
18. Koltai K, Kesmarky G, Feher G, Tibold A,
Toth K. Platelet Aggregometry Testing:
Molecular Mechanisms, Techniques and
Clinical Implications. Int J Mol Sci.
2017;18(8):1803.
19. Davies MJ. Detection and characterisation
of radicals using electron paramagnetic res-
onance (EPR) spin trapping and related
methods. Methods. 2016;109:21-30.
20. Hawkins CL, Davies MJ. Detection and
characterisation of radicals in biological
materials using EPR methodology. Biochim
Biophys Acta. 2014;1840(2):708-721.
21. Bedard K, Whitehouse S, Jaquet V.
Challenges, Progresses, and Promises for
Developing Future NADPH Oxidase
Therapeutics. Antioxid Redox Signal.
2015;23(5):355-357.
22. Diebold BA, Smith SM, Li Y, Lambeth JD.
NOX2 As a Target for Drug Development:
Indications, Possible Complications, and
Progress. Antioxid Redox Signal.
2015;23(5):375-405.
23. Pudusseri A, Shameem R, Spyropoulos AC.
A new paradigm shift in antithrombotic
therapy. Front Pharmacol. 2013;4:133.
24. Wong PC, Seiffert D, Bird JE, et al.
Blockade of protease-activated receptor-4
(PAR4) provides robust antithrombotic
activity with low bleeding. Sci Transl Med.
2017;9(371).
25. Pietraforte D, Vona R, Marchesi A, et al.
Redox control of platelet functions in phys-
iology and pathophysiology. Antioxid
Redox Signal. 2014;21(1):177-193.
26. Ranayhossaini DJ, Rodriguez AI, Sahoo S,
et al. Selective recapitulation of conserved
and nonconserved regions of putative
NOXA1 protein activation domain confers
isoform-specific inhibition of Nox1 oxidase
and attenuation of endothelial cell migra-
tion. J Biol Chem. 2013;288(51):36437-
36450.
27. Rey FE, Cifuentes ME, Kiarash A, Quinn
MT, Pagano PJ. Novel competitive inhibitor
of NAD(P)H oxidase assembly attenuates
vascular O(2)(-) and systolic blood pressure
in mice. Circ Res. 2001;89(5):408-414.
28. Csanyi G, Cifuentes-Pagano E, Al Ghouleh
I, et al. Nox2 B-loop peptide, Nox2ds,
specifically inhibits the NADPH oxidase
Nox2. Free Radic Biol Med.
2011;51(6):1116-1125.
29. Valente AJ, Jamali AE, Epperson TK,
Gamez MJ, Pearson DW, Clark RA. NOX1
NADPH oxidase regulation by the NOXA1
SH3 domain. Free Radic Biol Med.
2007;43(3):384-396.
30. Lopez JJ, Salido GM, Gomez-Arteta E,
Rosado JA, Pariente JA. Thrombin induces
apoptotic events through the generation of
reactive oxygen species in human platelets.
J Thromb Haemost. 2007;5(6):1283-1291.
31. Pignatelli P, Pulcinelli FM, Lenti L,
Gazzaniga PP, Violi F. Hydrogen peroxide is
involved in collagen-induced platelet acti-
vation. Blood. 1998;91(2):484-490.
32. Qiao J, Arthur JF, Gardiner EE, Andrews
RK, Zeng L, Xu K. Regulation of platelet
activation and thrombus formation by
reactive oxygen species. Redox Biol.
2018;14:126-130.
33. Chlopicki S, Olszanecki R, Janiszewski M,
Laurindo FRM, Panz T, Miedzobrodzki J.
Functional Role of NADPH Oxidase in
Activation of Platelets. Antioxid Redox
Signal. 2004;6(4):691-698.
34. Redondo PC, Jardin I, Hernandez-Cruz JM,
Pariente JA, Salido GM, Rosado JA.
Hydrogen peroxide and peroxynitrite
enhance Ca2+ mobilization and aggrega-
tion in platelets from type 2 diabetic
patients. Biochem Biophys Res Commun.
2005;333(3):794-802.
35. Furie B, Flaumenhaft R. Thiol isomerases in
thrombus formation. Circ Res. 2014;
114(7):1162-1173.
36. Jang JY, Min JH, Wang SB, et al. Resveratrol
inhibits collagen-induced platelet stimula-
tion through suppressing NADPH oxidase
and oxidative inactivation of SH2 domain-
containing protein tyrosine phosphatase-2.
Free Radic Biol Med. 2015;89:842-851.
37. Jang JY, Min JH, Chae YH, et al. Reactive
oxygen species play a critical role in colla-
gen-induced platelet activation via SHP-2
oxidation. Antioxid Redox Signal.
2014;20(16):2528-2540.
38. Mazharian A, Mori J, Wang YJ, et al.
Megakaryocyte-specific deletion of the
protein-tyrosine phosphatases Shp1 and
Shp2 causes abnormal megakaryocyte
development, platelet production, and
function. Blood. 2013;121(20):4205-4220.
39. Wang SB, Jang JY, Chae YH, et al.
Kaempferol suppresses collagen-induced
platelet activation by inhibiting NADPH
oxidase and protecting SHP-2 from oxida-
tive inactivation. Free Radic Biol Med.
2015;83:41-53.
40. Walsh TG, Berndt MC, Carrim N,
Cowman J, Kenny D, Metharom P. The
role of Nox1 and Nox2 in GPVI-dependent
platelet activation and thrombus forma-
tion. Redox Biol. 2014;2:178-186.
41. Obermayer G, Afonyushkin T, Binder CJ.
Oxidized low-density lipoprotein in
inflammation-driven thrombosis. J
Thromb Haemost. 2018;16(3):418-428.
42. Jaunmuktane Z, Mead S, Ellis M, et al.
Evidence for human transmission of amy-
loid-beta pathology and cerebral amyloid
angiopathy. Nature. 2015;525(7568):247-
250.
43. Donner L, Falker K, Gremer L, et al.
Platelets contribute to amyloid-beta aggre-
gation in cerebral vessels through integrin
alphaIIbbeta3-induced outside-in signaling
and clusterin release. Sci Signal. 2016;
9(429):ra52.
44. Blair TA, Moore SF, Hers I. Circulating
primers enhance platelet function and
induce resistance to antiplatelet therapy. J
Thromb Haemost. 2015;13(8):1479-1493.
45. Gresele P, Falcinelli E, Momi S. Potentiation
and priming of platelet activation: a poten-
tial target for antiplatelet therapy. Trends
Pharmacol Sci. 2008;29(7):352-60.
46. Carnevale R, Bartimoccia S, Nocella C, et
al. LDL oxidation by platelets propagates
platelet activation via an oxidative stress-
mediated mechanism. Atherosclerosis.
2014;237(1):108-116.
47. Abubaker AA, Vara D, Eggleston I,
Canobbio I, Pula G. A novel flow cytome-
try assay using dihydroethidium as redox-
sensitive probe reveals NADPH oxidase-
dependent generation of superoxide anion
in human platelets exposed to amyloid
peptide beta. Platelets. 2017;5:1-9.
48. Dayal S, Wilson KM, Motto DG, Miller FJ
Jr., Chauhan AK, Lentz SR. Hydrogen per-
oxide promotes aging-related platelet
hyperactivation and thrombosis.
Circulation. 2013;127(12):1308-1316.
49. Herczenik E, Bouma B, Korporaal SJ, et al.
Activation of human platelets by misfolded
proteins. Arterioscler Thromb Vasc Biol.
2007;27(7):1657-1665.
50. McFadyen JD, Schaff M, Peter K. Current
and future antiplatelet therapies: emphasis
on preserving haemostasis. Nat Rev
Cardiol. 2018;15(3):181-191.
